Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network.
Fremd C, Hack CC, Schneeweiss A, Rauch G, Wallwiener D, Brucker SY, Taran FA, Hartkopf A, Overkamp F, Tesch H, Fehm T, Hadji P, Janni W, Lüftner D, Lux MP, Müller V, Ettl J, Belleville E, Sohn C, Schuetz F, Beckmann MM, Fasching PA, Wallwiener M. Fremd C, et al. Arch Gynecol Obstet. 2017 May;295(5):1239-1245. doi: 10.1007/s00404-017-4348-2. Epub 2017 Mar 22. Arch Gynecol Obstet. 2017. PMID: 28331996
CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer.
Hlevnjak M, Schulze M, Elgaafary S, Fremd C, Michel L, Beck K, Pfütze K, Richter D, Wolf S, Horak P, Kreutzfeldt S, Pixberg C, Hutter B, Ishaque N, Hirsch S, Gieldon L, Stenzinger A, Springfeld C, Smetanay K, Seitz J, Mavratzas A, Brors B, Kirsten R, Schuetz F, Fröhling S, Sinn HP, Jäger D, Thewes V, Zapatka M, Lichter P, Schneeweiss A. Hlevnjak M, et al. Among authors: fremd c. JCO Precis Oncol. 2021 Apr 22;5:PO.20.00248. doi: 10.1200/PO.20.00248. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34036222 Free PMC article.
Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer.
Fischer C, Deutsch TM, Feisst M, Rippinger N, Riedel F, Hartkopf AD, Brucker SY, Domschke C, Fremd C, Michel L, Burwinkel B, Schneeweiss A, Turchinovich A, Wallwiener M. Fischer C, et al. Among authors: fremd c. Arch Gynecol Obstet. 2022 Sep;306(3):875-885. doi: 10.1007/s00404-022-06442-2. Epub 2022 Mar 2. Arch Gynecol Obstet. 2022. PMID: 35237856 Free PMC article.
COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy.
Pixberg C, Zapatka M, Hlevnjak M, Benedetto S, Suppelna JP, Heil J, Smetanay K, Michel L, Fremd C, Körber V, Rübsam M, Buschhorn L, Heublein S, Schäfgen B, Golatta M, Gomez C, von Au A, Wallwiener M, Wolf S, Dikow N, Schaaf C, Gutjahr E, Allgäuer M, Stenzinger A, Pfütze K, Kirsten R, Hübschmann D, Sinn HP, Jäger D, Trumpp A, Schlenk R, Höfer T, Thewes V, Schneeweiss A, Lichter P. Pixberg C, et al. Among authors: fremd c. ESMO Open. 2022 Dec;7(6):100637. doi: 10.1016/j.esmoop.2022.100637. Epub 2022 Nov 21. ESMO Open. 2022. PMID: 36423362 Free PMC article. Clinical Trial.
Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient.
Fremd C, Hlevnjak M, Zapatka M, Zoernig I, Halama N, Fejzibegovic N, Thewes V, Lichter P, Schirmacher P, Kloor M, Marmé F, Schütz F, Kosaloglu Z, Sinn HP, Jäger D, Schneeweiss A. Fremd C, et al. Breast Care (Basel). 2019 Mar;14(1):53-59. doi: 10.1159/000492580. Epub 2018 Nov 14. Breast Care (Basel). 2019. PMID: 31019444 Free PMC article.
23 results